Author:
Zhou Yang,Xu Shujing,López-Carrobles Nerea,Ding Dang,Liu Xinyong,Menéndez-Arias Luis,Zhan Peng
Abstract
Viral infections represent a major threat to human health and the global economy; however, most of the currently available antiviral drugs are not fully effective in restricting viral replication and selecting for drug-resistant variants. Targeted protein degradation technologies are promising strategies to avoid or delay the emergence of drug resistance. Among the protein degradation-based multi-specific approaches, proteolysis targeting chimera (PROTAC) is the main strategy applied in the antiviral field. In this review we will introduce the elements and mechanisms of action used by PROTAC technology, as well as the advantages of PROTACs over available antiviral drugs. We also summarize the latest progress in the application of PROTACs in antiviral research, discuss existing challenges and look into future opportunities for antiviral drug discovery.
Reference112 articles.
1. Epidemics and Trust: The Case of the Spanish Flu;A Aassve;Health Economics,2021
2. Pneumocystis Pneumonia--Los Angeles;Centers for Disease Control (CDC);MMWR Morbidity and Mortality Weekly Report,1981
3. Emerging Pandemic Diseases: How We Got to COVID-19;DM Morens;Cell,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献